Last reviewed · How we verify
Amodiaquine plus Artesunate co-administration
Amodiaquine plus Artesunate co-administration is a Small molecule drug developed by Kwame Nkrumah University of Science and Technology. It is currently FDA-approved.
Amodiaquine plus Artesunate co-administration, developed by Kwame Nkrumah University of Science and Technology, is a marketed antimalarial combination therapy. The key composition patent expires in 2028, providing a period of exclusivity and potential revenue protection. The primary risk is the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market adoption.
At a glance
| Generic name | Amodiaquine plus Artesunate co-administration |
|---|---|
| Sponsor | Kwame Nkrumah University of Science and Technology |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya
- Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon (PHASE3)
- Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Malaria in Cameroon (PHASE4)
- Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde (PHASE4)
- Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine for Falciparum Malaria in Zanzibar, 2005 (PHASE4)
- Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon (PHASE3)
- Intermittent Preventive Treatment (IPTp) Versus Rapid Diagnostic Testing (RDT) and Treatment of Malaria in Pregnancy (PHASE3)
- Dolutegravir Interactions With Artemisinin-based Combination Therapies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amodiaquine plus Artesunate co-administration CI brief — competitive landscape report
- Amodiaquine plus Artesunate co-administration updates RSS · CI watch RSS
- Kwame Nkrumah University of Science and Technology portfolio CI